Identification and characterization of a novel FBN1 gene variant in an extended family with variable clinical phenotype of Marfan syndrome

ABSTRACT Marfan syndrome (MFS) is a multi-systemic autosomal dominant condition caused by mutations in the gene (FBN1) coding for fibrillin-1. Mutations have been associated with a wide range of overlapping phenotypes. Here, we report on an extended family presenting with skeletal, ocular and cardiovascular clinical features. The 37-year-old male propositus, who had chest pain, dyspnea and shortness of breath, was first diagnosed based on the revised Ghent criteria and then subjected to molecular genetic analyses. FBN1 sequencing of the proband as well as available affected family members revealed the presence of a novel variant, c.7828G>C (p.Glu2610Gln), which was not present in any of the unaffected family members. In silico analyses demonstrated that the Glu2610 residue is part of the conserved DINE motif found at the beginning of each cbEGF domain of FBN1. The substitution of Glu2610 with Gln decreased fibrillin-1 production accordingly. Despite the fact that this variation appears to be primarily responsible for the etiology of MFS in the present family, our findings suggest that variable clinical expressions of the disease phenotype should be considered critically by the physicians.

[1]  G. Pals,et al.  Relationship between fibrillin-1 genotype and severity of cardiovascular involvement in Marfan syndrome , 2017, Heart.

[2]  Xiaogang Sun,et al.  Genetic testing of the FBN1 gene in Chinese patients with Marfan/Marfan-like syndrome. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[3]  B. Loeys.  The search for genotype/phenotype correlation in Marfan syndrome: to be or not to be? , 2016, European heart journal.

[4]  D. Roden,et al.  Performant Mutation Identification Using Targeted Next‐Generation Sequencing of 14 Thoracic Aortic Aneurysm Genes , 2015, Human mutation.

[5]  D. Reinhardt,et al.  Engineered mutations in fibrillin-1 leading to Marfan syndrome act at the protein, cellular and organismal levels. , 2015, Mutation research. Reviews in mutation research.

[6]  N. Fan,et al.  A novel mutation in fibrillin-1 gene identified in a Chinese family with marfan syndrome. , 2015, International journal of clinical and experimental medicine.

[7]  Michael Schroeder,et al.  PLIP: fully automated protein–ligand interaction profiler , 2015, Nucleic Acids Res..

[8]  M. Gross,et al.  The clinical presentation of Marfan syndrome is modulated by expression of wild-type FBN1 allele. , 2015, Human molecular genetics.

[9]  I. Michel-Behnke,et al.  Detection of 15 novel mutations in 52 children from 40 families with the Marfan or Loeys–Dietz syndrome and phenotype–genotype correlations , 2014, Clinical genetics.

[10]  L. Baudhuin,et al.  Increased frequency of FBN1 truncating and splicing variants in Marfan syndrome patients with aortic events , 2014, Genetics in Medicine.

[11]  G. Iyengar,et al.  Classical and Neonatal Marfan Syndrome Mutations in Fibrillin-1 Cause Differential Protease Susceptibilities and Protein Function* , 2011, The Journal of Biological Chemistry.

[12]  Laurence Faivre,et al.  The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.

[13]  Morten Nielsen,et al.  CPHmodels-3.0—remote homology modeling using structure-guided sequence profiles , 2010, Nucleic Acids Res..

[14]  M. Keane,et al.  Medical management of Marfan syndrome. , 2008, Circulation.

[15]  M Claustres,et al.  Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. , 2007, American journal of human genetics.

[16]  K. Rommel,et al.  Identification of 29 novel and nine recurrent fibrillin‐1 (FBN1) mutations and genotype–phenotype correlations in 76 patients with Marfan syndrome , 2005, Human mutation.

[17]  G. Jondeau,et al.  Molecular genetics of Marfan syndrome , 2005, Current opinion in cardiology.

[18]  G. Pals,et al.  Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome , 2004, Human mutation.

[19]  Jessica Geubtner,et al.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. , 2004, The Journal of clinical investigation.

[20]  H. Firth,et al.  Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? , 2003, Human molecular genetics.

[21]  P. Robinson,et al.  Mutations of FBN1 and genotype–phenotype correlations in Marfan syndrome and related fibrillinopathies , 2002, Human mutation.

[22]  Flemming Skovby,et al.  TGGE screening of the entire FBN1 coding sequence in 126 individuals with marfan syndrome and related fibrillinopathies , 2002, Human mutation.

[23]  L. Peltonen,et al.  Sensitivity of conformation sensitive gel electrophoresis in detecting mutations in Marfan syndrome and related conditions , 2002, Journal of medical genetics.

[24]  A. De Paepe,et al.  Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. , 2001, Archives of internal medicine.

[25]  U. Francke,et al.  Multi-exon deletions of the FBN1 gene in Marfan syndrome , 2001, BMC Medical Genetics.

[26]  D. Reinhardt,et al.  Mutations in Calcium-binding Epidermal Growth Factor Modules Render Fibrillin-1 Susceptible to Proteolysis , 2000, The Journal of Biological Chemistry.

[27]  U. Francke,et al.  Cysteine substitutions in epidermal growth factor-like domains of fibrillin-1: distinct effects on biochemical and clinical phenotypes. , 1999, American journal of human genetics.

[28]  I. Campbell,et al.  Solution Structure of a Pair of Calcium-Binding Epidermal Growth Factor-like Domains: Implications for the Marfan Syndrome and Other Genetic Disorders , 1996, Cell.

[29]  P. Byers,et al.  Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene. , 1996, American journal of medical genetics.

[30]  H. Dietz,et al.  Mutations in the human gene for fibrillin-1 (FBN1) in the Marfan syndrome and related disorders. , 1995, Human molecular genetics.

[31]  U. Francke,et al.  Fibrillin abnormalities and prognosis in Marfan syndrome and related disorders. , 1995, American journal of medical genetics.

[32]  D. Milewicz,et al.  A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome. , 1995, The Journal of clinical investigation.

[33]  B. Sykes,et al.  Genomic organization of the sequence coding for fibrillin, the defective gene product in Marfan syndrome. , 1993, Human molecular genetics.

[34]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[35]  Georg E. Schulz,et al.  Principles of Protein Structure , 1979 .

[36]  L. Sakai,et al.  Biogenesis and function of fibrillin assemblies , 2009, Cell and Tissue Research.

[37]  Flemming Skovby,et al.  Classic, atypically severe and neonatal Marfan syndrome: twelve mutations and genotype–phenotype correlations in FBN1 exons 24–40 , 2001, European Journal of Human Genetics.